exRNAdisease

Entry Detail

---



General Information

Database ID: exR0089331 RNA Name: hsa-miR-769-5p RNA Type: miRNA Chromosome: chr19 Starnd: + Coordinate: Start Site(bp): 46018961 End Site(bp): 46018982 External Links: hsa-miR-769-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ACVR1B chr12 51951699 51997078 + ANGEL1 chr14 76786168 76826246 - ASB1 chr2 238426742 238452250 + BMPR2 chr2 202376327 202567751 + CAPNS1 chr19 36139953 36150353 + CBFB chr16 67028984 67101058 + CLDN11 chr3 170418865 170454733 + CLN8 chr8 1755778 1801711 + DBNDD1 chr16 90004871 90020128 - DCTN4 chr5 150708440 150759109 - EIF1AD chr11 65996545 66002176 - EIF1AX chrX 20124525 20141838 - FOXK1 chr7 4682295 4771442 + LONRF2 chr2 100271875 100322501 - MDM4 chr1 204516379 204558120 + MRTO4 chr1 19251805 19260128 + NUSAP1 chr15 41320794 41381050 + PLCD3 chr17 45108959 45133354 - PRKAA1 chr5 40759379 40798374 - PXN chr12 120210439 120265771 - RHPN1 chr8 143368876 143384221 + RUNX1 chr21 34787801 36004667 - TFAP4 chr16 4257186 4273075 - VAT1 chr17 43014607 43025123 - YPEL5 chr2 30146941 30160533 + ZDHHC9 chrX 129803288 129843909 - miRNA targets: NA circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC245033.4 chr15 82533175 82540008 - LINC00324 chr17 8220642 8224043 - MALAT1 chr11 65497688 65506516 + SNHG1 chr11 62851984 62855953 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.